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Abstract
Faropenem is a new oral penem with a structure different from current b-lactams including carbapenems. The susceptibility of
Streptococcus pneumoniae , Haemophilus influenzae and Moraxella catarrhalis to faropenem, a macrolide, a b-lactam, a b-lactam/b-
lactamase inhibitor combination and two fluoroquinolones was investigated. S. pneumoniae was the most susceptible of the three
species to faropenem. The MIC90s of faropenem against M. catarrhalis and H. influenzae were 0.5 and 1 mg/l, respectively. They
were similar to amoxiclav (MIC 90s of 0.25 and 0.5 mg/l). The quinolones showed strong activity against H. influenzae . A cluster
analysis of the activities of amoxycillin and faropenem demonstrated a direct relationship between the two antimicrobial agent’s
activities and resistance profiles against both S. pneumoniae and H. influenzae .
# 2003 Elsevier Science B.V. and the International Society of Chemotherapy. All rights reserved.
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1. Introduction
Faropenem is a new oral penem antimicrobial agent,
which has an unsaturated thiazole ring and is a
structural hybrid between the penicillin and carbapenem
nucleus (Fig. 1). It is characterised by potent penicillin
binding protein activity and b-lactamase stability. The
antibacterial spectrum of faropenem includes Gram-
positive, Gram-negative and some anaerobic bacteria
[1]. In common with other b-lactams, target modifica-
tions via altered penicillin-binding proteins (PBPs) have
previously been shown to increase the minimum inhibi-
tory concentration (MIC) of faropenem for respiratory
tract infections compared with wild type strains [2].
Faropenem typically shows high affinity for PBPs
compared with other agents. Respiratory tract infections
are a major cause of morbidity and mortality in the
community and hospitals. Streptococcus pneumoniae ,
Moraxella catarrhalis and Haemophilus influenzae are
common causes of lower respiratory tract infections
(LRTIs) and upper respiratory tract infections (URTIs).
Worldwide, the annual incidence of community-ac-
quired pneumonia (CAP) is estimated to be 1.1/4.0
per 1000 population. In the UK CAP accounts for 5/
12% of cases of LRTIs among adults approximately 20/
42% of which require hospitalisation [3].
This study compared the in vitro activity of farope-
nem against S. pneumoniae , M. catarrhalis and H.
influenzae isolated in the UK with amoxycillin, amox-
iclav, clarithromycin, levofloxacin and ciprofloxacin
activity.
2. Materials and methods
2.1. Antimicrobial agents
The following antimicrobial agents were studied:
faropenem and ciprofloxacin (Bayer), amoxycillin (CP
Pharmaceuticals), amoxiclav (SmithKline Beecham
Pharmaceuticals and CP Pharmaceuticals), clarithromy-
cin (Abbott) and levofloxacin (Aventis Pharma Ltd.).
The antimicrobial agents were stored and prepared
according to the suppliers’ instructions. The amoxiclav
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consisted of fixed concentrations of 2 mg/l of clavulanic
acid per plate and doubling dilutions of amoxycillin [4].
2.2. Bacterial strains
S. pneumoniae (n/100) from Edinburgh and Leeds,
M. catarrhalis (100) from Edinburgh, Leeds and Wales
and H. influenzae (100) from Edinburgh and Glasgow,
collected between 1997 and 2000, were used in this
study. The control strains comprised S. pneumoniae
NCTC 13593, Staphylococcus aureus NCTC 6571, H.
influenzae NCTC 11931 and a laboratory reference
strain of M. catarrhalis .
2.3. Susceptibility testing
MICs were determined by standard agar dilution
methods according to the BSAC guidelines for sensitiv-
ity testing [4] on Columbia agar (Oxoid, Basingstoke)
supplemented with 5% defibrinated horse blood for S.
pneumoniae and M. catarrhalis and chocolate Columbia
agar plates for H. influenzae .
A final concentration of 105 cfu per spot of S.
pneumoniae and 104 cfu per spot of H. influenzae and
M. catarrhalis were inoculated onto each plate. The
plates were incubated aerobically.
3. Results
The MICs of faropenem and the comparators are
given in Table 1.
For S. pneumoniae , faropenem had the lowest MIC50
(0.008 mg/l) and MIC90 (0.25 mg/l) of all the antimicro-
bial agents tested. The faropenem modal MIC against S.
pneumoniae was 0.008 mg/l for 39 isolates, which was
also the lowest concentration compared with 0.016 mg/l
(37 isolates) for amoxiclav, 0.016/0.032 mg/l for amox-
ycillin against 70 isolates, 0.032 mg/l (42 isolates) for
clarithromycin and 1 mg/l for both levofloxacin (48
isolates) and ciprofloxacin (28 isolates).
Faropenem had the second largest MIC90 and the
second highest range endpoint against M. catarrhalis .
The quinolones levofloxacin and ciprofloxacin had the
lowest MIC90s at 0.06 mg/l. The modal MICs of
faropenem were 0.06 mg/l, for 27 isolates and 0.25 mg/
l for 25 isolates of M. catarrhalis . Levofloxacin and
ciprofloxacin inhibited 66 and 73 strains of M. catar-
rhalis , respectively, at 0.032 mg/l. The mode MIC of
clarithromycin was 0.12 mg/l, which inhibited 54
isolates. Amoxiclav did not have a mode concentration
against M. catarrhalis . Amoxiclav inhibited 17 isolates
at 0.004, 0.008 and 0.6 mg/l; 16 isolates had amoxiclav
MICs of 0.12 mg/l, 12 isolates had MICs of 0.002 mg/l,
nine had MICs of 0.25 mg/l, eight were inhibited by
0.032 mg/l and four isolates were inhibited by 0.016 mg/
l. The mode concentration of amoxycillin was between 1
and 4 mg/l and inhibited 61 isolates.
The MIC50 and MIC90 of faropenem for H. influenzae
were 0.5 and 1 mg/l, respectively. Clarithromycin had an
MIC50 and MIC90 of 4 and 8 mg/l. Both quinolones had
MIC50 and MIC90s of six doubling dilutions lower than
faropenem. However, the results of faropenem were
Fig. 1. Faropenem chemical structure.
Table 1
MIC values of the antimicrobial agents
Organism (number) Antimicrobial agent MIC50 (mg/l) MIC90 (mg/l) Range (mg/l) Mode MIC (mg/l), [number of strains]
S. pneumoniae (100) Faropenem 0.008 0.25 0.002/1 0.008 [39]
Amoxycillin 0.032 0.5 0.004/2 0.016 [36]/0.032 [34]
Amoxiclav 0.016 0.5 0.004/2 0.016 [37]
Clarithromycin 0.06 2 0.008//32 0.032 [42]
Levofloxacin 1 2 0.12/2 1 [48]
Ciprofloxacin 1 4 0.032/8 1 [28]
M. catarrhalis (100) Faropenem 0.12 0.5 0.032/1 0.06 [27]/0.25 [25]
Amoxycillin 1 4 0.016/8 1 [16]/2 [20]/4 [25]
Amoxiclav 0.016 0.25 0.002/0.25 0.004 [17]/0.008 [17], 0.06 [17]/0.12 [16]
Clarithromycin 0.12 0.12 0.032/0.25 0.12 [54]
Levofloxacin 0.032 0.06 0.016/0.12 0.032 [66]
Ciprofloxacin 0.032 0.06 0.016/0.06 0.032 [73]
H. influenzae (100) Faropenem 0.5 1 0.06/4 0.5 [48]
Amoxycillin 0.5 4 B/0.032/32 0.5 [50]
Amoxiclav 0.25 0.5 0.016/2 0.25 [33]/0.5 [40]
Clarithromycin 4 8 B/0.06/16 8 [36]
Levofloxacin 0.008 0.016 0.004/1 0.008 [43]
Ciprofloxacin 0.008 0.016 B/0.004/2 0.008 [66]
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Fig. 2. Cluster analysis of amoxycillin and faropenem activity.
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comparable with amoxiclav, which had lower MIC50
and MIC90 values than faropenem, but only by one
doubling dilution. The MIC50 and MIC90 of amoxycillin
against H. influenzae were 0.5 and 4 mg/l, respectively.
The mode MIC of faropenem for H. influenzae was 0.5
mg/l for 48 isolates compared with 0.008 mg/l for
levofloxacin and ciprofloxacin against 43 and 66 iso-
lates, respectively.
The results suggest that there might be a direct
correlation between the sensitivity to amoxycillin and
to faropenem. So a cluster analysis of faropenem and
amoxycillin MICs against S. pneumoniae , M. catarrhalis
and H. influenzae was performed (Fig. 2). The two
graphs have the same distribution patterns and both
indicate that there is a direct relationship between
amoxycillin and faropenem inhibition of S. pneumoniae
and H. influenzae . As resistance to amoxycillin in-
creases, there is a proportional increase in resistance to
faropenem. The correlation with M. catarrhalis is less
pronounced and does not occur until high levels of
penicillin resistance are reached. Thus, strains of S.
pneumoniae and in many cases, H. influenzae isolates,
resistant to amoxycillin due to alterations in penicillin
binding proteins are also able to confer resistance to
faropenem [7]. Those strains where b-lactamase resis-
tance is more prominent, particularly M. catarrhalis
show less resistance to faropenem.
4. Discussion
The faropenem results obtained in this study agree
with previously reported data and indicate that it has
significant activity (MIC905/1 mg/l) against respiratory
tract infections such as S. pneumoniae , M. catarrhalis
and H. influenzae [5,6]. The activity of faropenem was
usually of a similar level to that of amoxiclav. This is
perhaps not surprising as the clavulanic acid component
of amoxiclav removes the b-lactamase contribution to
amoxycillin resistance and faropenem is b-lactamase
stable. This is emphasised by the correlation between
amoxycillin and faropenem inhibition shown in Fig. 2.
These cluster analyses show a direct relationship be-
tween faropenem and amoxycillin sensitivities demon-
strating that faropenem was not capable of over-coming
the resistance mechanisms arising from alteration of
penicillin binding proteins in S. pneumoniae . The
correlation was also quite clear in H. influenzae , where
much of the amoxycillin resistance is mediated by
mechanisms other than b-lactamase hydrolysis [7].
There is less obvious correlation in M. catarrhalis ,
where b-lactamase hydrolysis is a more prominent
mechanism of amoxycillin hydrolysis [8]. In this case,
there is a major increase in amoxycillin resistance
without a significant change in faropenem resistance.
It is only after a threshold is reached that further
increases in amoxycillin resistance correspond with
concomitant increases in faropenem resistance. As
anticipated the two quinolones tested had lower
MIC50 and MIC 90 values than all the agents tested
for H. influenzae and all the agents except amoxiclav for
M. catarrhalis . In these in vitro tests clarithromycin
does not perform as well as faropenem against S.
pneumoniae or H. influenzae . The results of faropenem
demonstrate that it is a potent drug but these results
suggest that the acquisition of penicillin resistance
would have an adverse effect on faropenem in S.
pneumoniae and H. influenzae but less so in M.
catarrhalis .
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